Total amount raised
$270.5M
Latest funding date
2024-07-22
Location
Loyal has successfully raised funds from 20 investors, including Collaborative Fund and Valor Equity Partners, participating in a Series B funding round. The company is focused on developing medicines to extend the lifespan and improve the quality of life for dogs.
What Is Loyal?
Loyal, founded in 2019 by Celine Halioua, is a biotechnology company based in San Francisco, California. The company focuses on developing medicines to extend the lifespan and improve the quality of life for dogs.
Operating in the biotechnology, pet, and veterinary industries, Loyal employs between 101-250 people. The company aims to slow the aging process in dogs, thereby delaying or preventing age-related diseases such as cancer and dementia.
How Much Funding Has Loyal Raised?
- Seed Round
- Amount Raised: $11M
- Date: December 2019
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To kickstart the company's research and development efforts in biotechnology for extending the lifespan of dogs.
- Venture Round
- Amount Raised: Not publicly disclosed
- Date: June 2020
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To further develop and validate their initial research findings.
- Series A
- Amount Raised: $27M
- Date: September 2021
- Lead Investors: Khosla Ventures
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand their research team and accelerate the development of their biotechnology solutions. Participants included First Round Capital, Box Group, Collaborative Fund, The Longevity Fund, and Lachy Groom.
- Series A Extension
- Amount Raised: $20M
- Date: April 2022
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To continue their research and prepare for clinical trials.
- Series B
- Amount Raised: $45M
- Date: March 2024
- Lead Investors: Bain Capital Ventures
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To fund large-scale clinical trials and advance their drug development pipeline. New investor Valor Equity Partners also joined, alongside existing investors Khosla Ventures, First Round Capital, Box Group, Collaborative Fund, and Quiet Capital.
- Debt Financing
- Amount Raised: $12M
- Date: March 2024
- Lead Investors: Bridge Bank (division of Western Alliance Bank)
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To provide additional working capital for ongoing projects.
- Series B Extension
- Amount Raised: $33.5M
- Date: July 2024
- Lead Investors: Concord Health Partners
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To continue advancing clinical programs and support ongoing drug development efforts.
- Series B-2
- Amount Raised: $22M
- Date: February 2025
- Lead Investors: Collaborative Fund, Valor Equity Partners
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To advance clinical programs and prepare for potential commercialization of their longevity-focused veterinary pharmaceuticals.
- Series C
- Amount Raised: $100M
- Date: February 2026
- Lead Investors: age1
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To advance LOY-002 toward FDA approval, cover commercial launch preparation, expand the team, and invest in Loyal's scientific platform. Baillie Gifford and existing investors also participated.
Total Amount Raised: At least $270.5M based on disclosed funding (across all rounds with known amounts: $11M + $27M + $20M + $45M + $12M + $33.5M + $22M + $100M).
Current Valuation: Not publicly disclosed
Key Investors
- age1
- Details: age1 is a longevity-focused venture fund and the lead investor in Loyal's $100M Series C (February 2026). The fund was co-founded by Alex Colville and represents the next generation of Laura Deming's The Longevity Fund.
- Investment Focus Areas: Longevity science, life extension
- Notable Investments: Loyal (Series C lead)
- Collaborative Fund
- Details: Collaborative Fund is a venture capital firm that invests in companies focused on sustainability, health, and wellness. It co-led Loyal's Series B-2 in February 2025.
- Investment Focus Areas: Sustainability, health, wellness
- Notable Investments: Participated in Loyal's Seed, Series A, Series B, and Series B-2 rounds
- Valor Equity Partners
- Details: Valor Equity Partners is a private equity firm that invests in high-growth companies across various sectors. It co-led the Series B-2 and joined as a new investor in the Series B.
- Investment Focus Areas: High-growth companies across various sectors
- Notable Investments: Participated in Loyal's Series B and Series B-2 rounds
- Bridge Bank
- Details: Bridge Bank is a division of Western Alliance Bank that provides financial services to small and mid-sized businesses. It provided Loyal's $12M debt facility in March 2024.
- Investment Focus Areas: Financial services for small and mid-sized businesses
- Notable Investments: Loyal debt financing (March 2024)
- Bain Capital Ventures
- Details: Bain Capital Ventures is a venture capital firm that invests in early to growth-stage companies across multiple industries. It led Loyal's $45M Series B in March 2024.
- Investment Focus Areas: Early to growth-stage companies across multiple industries
- Notable Investments: Lead investor in Loyal's Series B
- Khosla Ventures
- Details: Khosla Ventures is a venture capital firm that focuses on early-stage investments in technology and healthcare. It led Loyal's Series A and has participated in multiple subsequent rounds.
- Investment Focus Areas: Technology, healthcare
- Notable Investments: Lead investor in Loyal's Series A; participant in Series B
What's Next for Loyal?
Loyal stands at the cusp of a transformative era in veterinary medicine, with the potential to revolutionize the longevity and health of dogs. The company's recent FDA RXE acceptance for LOY-002 and substantial funding indicate a promising future. As they advance clinical trials and prepare for commercialization, the opportunities for growth are immense.
Future fundraising efforts will likely focus on supporting these large-scale clinical trials and navigating the regulatory landscape. However, challenges such as proving drug efficacy and safety, and facing competition in the veterinary sector, remain. Loyal's journey is poised to be a significant chapter in the evolution of pet health.
Use Clay to Get Funding Data
Sales professionals, take your strategy to the next level by leveraging Clay's platform to access comprehensive fundraising data on companies like Loyal and gather other critical business insights.
Sign up for free to start exploring the wealth of information available at your fingertips and gain a competitive edge in your sales efforts.
